tiprankstipranks
CinCor Pharma downgraded to Equal Weight from Overweight at Barclays
The Fly

CinCor Pharma downgraded to Equal Weight from Overweight at Barclays

Barclays analyst Leon Wang downgraded CinCor Pharma (CINC) to Equal Weight from Overweight with a price target of $31, up from $22, after the company enter into an agreement to be acquired by AstraZeneca (AZN). The anlayst thinks the contingent value right is worth $5 per share.

Published first on TheFly

See today’s best-performing stocks on TipRanks >>

Read More on CINC:

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100
Bitcoin

Popular Articles